Determine the necessary mass, volume, or concentration for preparing a solution.
≥99% for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at -20°C Ships Ice chest + Ice pads Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Atuveciclib (BAY-1143572) is a potent and highly selective, oral PTEFb / CDK9 inhibitor. Atuveciclib (BAY-1143572) inhibits CDK9 / CycT1 with an IC 50 of 13 nM.
Appearance:Solid
IC50& Target:CDK9/CycT1 13 nM (IC 50 ) CDK9/CycT1(h) 6 nM (IC 50 ) CDK3/CycE(h) 890 nM (IC 50 ) CDK2/CycE(h) 1000 nM (IC 50 ) CDK1/CycB(h) 1100 nM (IC 50 ) CDK5/p35(h) 1600 nM (IC 50 )
In Vitro:Positive transcription elongation factor b (PTEFb) is a heterodimer of CDK9 and one of four cyclin partners, cyclin T1, cyclin K, cyclin T2a or cyclin T2b. Atuveciclib (BAY-1143572) demonstrates potent antiproliferative activity against HeLa cells (IC 50
In Vivo:In vivo efficacy studies in the MOLM-13 xenograft model in mice, Atuveciclib (BAY-1143572) demonstrates great potency and high antitumor efficacy. Daily administration of Atuveciclib (BAY-1143572) at 6.25 or 12.5mg/kg results in a dose-dependent antitumo
Biological Activity:Atuveciclib (BAY-1143572) is a potent and highly selective, oral PTEFb / CDK9 inhibitor. Atuveciclib (BAY-1143572) inhibits CDK9 / CycT1 with an IC 50 of 13 nM.
| Peso molecular | 387.43 |
|---|
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →| Solubilidad | DMSO : ≥ 128.5 mg/mL (331.67 mM) |
|---|